Featured Content

Winston Wong, PharmD
President, W-Squared Group

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma

(Yahoo! Finance) Oct 13, 2014 - Bristol-Myers Squibb Company, Pharmacyclics, Inc., and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib).

Commentary: Two drugs which are very effective in their own right. Combined, project the results, and then the demand, and...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer

(Johnson & Johnson) Oct 17, 2014 - Janssen-Cilag International NV announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor.
read corporate press release »

NICE Backs Novartis' Glivec For GIST

(PharmaTimes [UK]) Oct 17, 2014 - Novartis’ stomach tumour therapy Glivec (imatinib) is a giant leap closer to being funded by the NHS in England after cost regulators again endorsed its use.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma (Yahoo! Finance)

Two drugs which are very effective in their own right. Combined, project the results, and then the demand, and...posted by: Winston Wong, PharmD

ASCO Endorses CAP/IASLC/AMP Guideline on EGFR and ALK Molecular Testing for Patients with Lung Cancer (ASCO)

While I am glad to see ASCO endorsing such testing, such testing, from the eyes of the payer, is accepted as standard...posted by: Winston Wong, PharmD

'Parity' Laws for Costly Oral Cancer Drugs Not a Solution (Medscape Medical News)

Call it a shell game where the added cost liability of the payer is passed onto the general membership through...posted by: Winston, Wong, PharmD

Cancer Care Is Advancing, But Costs Cannot Be Ignored (Yahoo! Finance)

Dr Newcomer provides a powerful arguments addressing the advancement of oncology care, associated with increasing...posted by: Winston, Wong, PharmD

Ascension Health Bans Genentech Sales Reps After Losing Drug Discounts (PharmTech.com)

If I am not mistaken, Genentech tried this same strategy about two years ago. The argument for safe distribution...posted by: Phyllis Stanley






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.


Novocure has posted 4 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
APRI +27.13%
REGN +8.49%
SRNE +7.53%
ARWR -8.12%
MYGN -7.23%
NKTR -6.59%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: H2 2014
Company: Amgen
Product: Trebananib

Date: September / October 2014
Company: Seattle Genetics / Takeda
Product: Adcetris® (brentuximab vedotin)

Date: Q4 2014
Company: Bristol-Myers Squibb / Ono Pharmaceutical Co.
Product: Opdivo® (nivolumab)

See All OBR Radar items»